Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 51Active not recruiting 33Recruiting 22Terminated 21Withdrawn 9Not yet recruiting 5Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cisplatin 512Radiotherapy 376Cyclophosphamide 361Carboplatin 354Capecitabine 341Oxaliplatin 331Paclitaxel 328Gemcitabine 318Docetaxel 314Fluorouracil 288Drug Therapy 271apatinib 245Bevacizumab 243camrelizumab 217Etoposide 200Irinotecan 182Doxorubicin 180Leucovorin 160Dexamethasone 160pembrolizumab 150sintilimab 143Neoadjuvant Therapy 142anlotinib 139Pemetrexed 138Cytarabine 138Blood Specimen Collection 138Surgical Procedures, Operative 130toripalimab 128Radiosurgery 127S 1 (combination) 124

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × auricularum × Clear all
NCT03252600 2023-01-25

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Barbara Ann Karmanos Cancer Institute

Phase 2 Unknown
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡